Imunon Inc
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Imunon Inc’s stock, expecting its price to rise to $9.
Financial Health
Imunon Inc has decent cash flow and book value, indicating steady financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IMNN
Pharma's Private Equity Pivot: The Immunology Opportunity
Bristol Myers Squibb has partnered with Bain Capital to launch a new immunology-focused firm, highlighting a trend of pharma giants spinning out assets with private equity backing. This creates an investment opportunity in specialized biotech companies and the broader drug development ecosystem that supports them.
Published: July 29, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Early‑stage science
Novel immunotherapy research can deliver step‑change outcomes, though clinical and regulatory hurdles make results uncertain. Investors should expect long timelines and binary trial readouts.
Catalysts to watch
Key events include clinical data releases, partnership deals and financing rounds; these can move the stock sharply, but outcomes may be unpredictable.
Market and partners
Collaborations and licensing can validate technology and fund development, but competitive dynamics and manufacturing scale remain important risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
